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Does Radical Cystectomy Improve Overall Survival in 
Octogenarians with Muscle-Invasive Bladder Cancer?
Sangjun Yoo, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Purpose: We compared the efficacy of radical cystectomy (RC) and non-RC treatment 
[transurethral resection of bladder tumor (TURB) only, partial cystectomy, or TURB 
followed by radiotherapy] in octogenarians with muscle-invasive bladder cancer 
(MIBC).
Materials and Methods: A total of 177 patients aged 80 years or more underwent TURB 
at our institute, and 41 patients had MIBC according to the histologic examination. 
Fourteen patients with lymph node or distant metastasis were excluded, and 27 pa-
tients were ultimately included. Patients were stratified by treatment modality (RC 
vs. non-RC), Charlson Comorbidity Index (low CCI vs. high CCI), and clinical tumor 
stage (organ-confined disease vs. extravesical disease). The effects of several variables 
on cancer-specific and overall survival were assessed.
Results: Of the 27 patients, 11 (41%) underwent RC and 16 (59%) underwent non-RC 
treatment. Patients in the RC group were younger and more likely to have low CCI 
scores. There were no significant differences in overall or cancer-specific survival in 
the RC and non-RC groups. Patients with clinically organ-confined disease had better 
survival outcomes than did those with extravesical disease. Stratification of patients 
by CCI indicated that overall survival was better in patients with low CCI scores 
(p=0.013), although cancer-specific survival was similar in the two CCI groups. 
Univariate and multivariate analysis indicated that clinical tumor stage and CCI were 
independently associated with overall survival.
Conclusions: RC in octogenarians with MIBC does not improve overall survival com-
pared with other treatment modalities. However, clinically organ-confined disease and 
low CCI score were associated with better overall survival. 
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INTRODUCTION
Bladder cancer is a common malignancy that disproportio-
nately affects the elderly. The National Cancer Institute 
(NCI) Surveillance, Epidemiology, and End Results 
(SEER) Program estimated that most bladder carcinoma 
patients are 65 years or older at the time of diagnosis, and 
that the median age at diagnosis is 73 years [1]. In the 
United States, bladder cancer is the fourth leading cause 
of cancer-related mortality in men aged 80 years or older 
[2].
　Bladder cancer is a heterogeneous disease. Most bladder 
cancers are superficial tumors, and such patients have ex-
cellent prognoses. However, patients whose bladder cancer 
has invaded the proper muscle have poorer prognoses, and 
20% to 40% of such patients present with or develop mus-
cle-invasive bladder cancer (MIBC). In these cases, radical 
cystectomy (RC) is the gold standard treatment. However, 
this treatment can be associated with complications and 
poor quality of life. Thus, several studies have examined 
the use of a bladder-sparing technique to manage MIBC, 
especially in the elderly [3-5].Korean J Urol 2011;52:446-451
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　Age is often a major consideration when considering 
treatment options for MIBC. Data from multiple small sur-
gical series have demonstrated that selected older patients 
fare comparably to their younger counterparts in terms of 
early and late complications and perioperative outcomes 
[6-8]. However, other reports suggested that advanced age 
may be an independent predictor of adverse oncologic and 
overall survival outcomes [9,10].
　Treatment decisions for elderly patients with MIBC re-
main a significant and difficult clinical challenge. Several 
factors such as life expectancy, natural history of the can-
cer, and availability of multiple treatment modalities and 
complications should be considered. However, no previous 
study has compared the impact of different treatment mo-
dalities on the overall survival of octogenarians with 
MIBC. Thus, in the present study, we compared the surviv-
al outcomes of octogenarians with MIBC who underwent 
different treatments and identified the variables asso-
ciated with overall survival. 
MATERIALS AND METHODS
1. Patients
From January 1991 to December 2010, a total of 177 pa-
tients aged 80 years or more underwent transurethral re-
section of bladder tumor (TURB) for urothelial carcinoma 
of the bladder at our institute. Forty-one of these patients 
(23.2%) had urothelial carcinoma with proper muscle in-
vasion according to the histological examination. Fourteen 
of these patients had lymph node involvement or distant 
metastases on preoperative imaging and were excluded. 
Finally, 27 patients were included in our study cohort. 
Eleven of these patients underwent radical cystectomy 
(RC) and 16 patients underwent an alternative treatment 
(non-RC), which was TURB only (9 patients), partial cys-
tectomy (4 patients), or TURB followed by radiotherapy (3 
patients). Each patient was informed of the advantages 
and disadvantages of each procedure and decided on treat-
ment after consultation with an urologist. In the 9 patients 
who underwent TURB only, bladder cancer was grossly 
completely removed in 4 patients, and 5 patients under-
went TURB for palliation. In patients with TURB followed 
by radiotherapy, bladder cancer was completely removed 
before radiotherapy. RC was performed in patients with 
minimal comorbidities who were aware of possible compli-
cations and was performed with same surgical procedures 
in all 11 patients (standard bilateral pelvic lymph node dis-
section with en bloc RC followed by ileal conduit). Partial 
cystectomy was performed if the patient had a solitary 
bladder tumor, and the goal was resection of the tumor and 
laterally at the margins to include at least 2 cm of nor-
mal-appearing mucosa. Patients who refused surgical 
management after TURB were treated with radiotherapy, 
which consisted of a standard fractionation scheme of 30 
fractions of 2 Gy (total dose, 60 Gy) over 30 days. Patients 
with severe comorbidities who refused further manage-
ment after TURB were conservatively managed after ad-
equate consultation.
2. Clinical and pathologic evaluation
Tumor stage and grade were recorded according to the 2010 
TNM system and the 1973 WHO system, respectively 
[11,12]. All patients underwent chest radiography, com-
puted tomography (CT) of the abdomen and pelvis, and 
bone scans for tumor staging before treatment. Age, sex, 
clinical stage, pathologic stage, comorbid conditions, and 
American Society of Anesthesiologists (ASA) score were ob-
tained from the hospital database. Comorbid conditions at 
the time of treatment were obtained retrospectively from 
the preoperative clinical records. There were no systematic 
changes over the study period in the methods of acquiring 
patient comorbidity data. Charlson Comorbidity Index 
(CCI) scores, in which comorbid conditions are weighted 
and scored, were calculated as described by Charlson [13]. 
All complications occurring within 90 days after initiation 
of treatment were identified and graded according to an es-
tablished 5-grade modification of the original Clavien sys-
tem [14].
3. Statistical analysis
The causes of death were obtained from medical charts and 
death certificates. Patients were routinely evaluated by 
clinical and radiographic work-ups to identify possible evi-
dence of disease. Patient groups were compared according 
to treatment modality (RC group vs. non-RC group) and 
CCI [low (CCI=0) vs. high (CCI≥1)] using Pearson’s chi- 
square test for categorical variables and the Mann-Whit-
ney U test for continuous variables. Quantitative data were 
expressed as means±standard deviations. Cancer-specific 
survival and overall survival were measured from the date 
of initiation of treatment to the date of death from bladder 
cancer or other causes. Kaplan-Meier survival curves were 
used to estimate cancer-specific survival and overall sur-
vival according to treatment modality, tumor stage, and 
CCI and were compared by using the log rank test. Cox re-
gression was performed to define independent factors asso-
ciated with overall survival. All statistical tests were 
2-tailed, and a p-value less than 0.05 was considered 
significant. All statistical analyses were performed by us-
ing the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Table 1 shows the characteristics of our patient cohort. The 
mean age was 82.5 years (IQR: 81-83) and 23 patients 
(85.2%) were males. According to preoperative CT scans, 
clinically extravesical disease was suspected in 16 patients 
(59.3%). Patients in the RC group were younger than those 
in the non-RC group (p＜0.001). There was no statistically 
significant difference in the CCI and ASA scores of these 
two groups, but the RC group tended to have lower CCI 
scores (p=0.079). After treatment, patients in the RC group 
had a longer mean hospital stay (p＜0.001) and experi-
enced more major complications, defined as a Clavien Korean J Urol 2011;52:446-451
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TABLE 3. Characteristics of the four patients who died from bladder cancer
Treatment
modality
Age
(yr)
Gender
Clinical
stage
Pathologic
stage
Tumor
grade
Recurrence
(months)
Death
(months)
CCI
1
2
3
4
TURB
PC
RC
RC
83
87
81
80
Male
Male
Male
Male
T3N0
T2N0
T2N0
T4N0
-
T3bNX
T3bN0
T4aN0
3
3
3
3
  3.7
14.9
19.3
  4.5
10.9
20.5
27.5
19.4
1
0
1
0
TURB: transurethral resection of bladder tumor, PC: partial cystectomy, RC: radical cystectomy, CCI: Charlson comorbidity index
TABLE 1. Clinicopathologic characteristics of the study cohort 
according to treatment modality
Total RC group
Non-RC
group
p-value
No. patients
Mean age±SD, years
No. gender (%)
    Male
    Female
No. CCI (%)
    Low (CCI=0)
    High (CCI≥1)
No. ASA score (%)
    Low (1-2)
    High (3-4)
No. clinical tumor 
  stage (%)
    Organ confined
    Extravesical
No. tumor grade (%)
    Grade 2
    Grade 3 
Mean durationof 
  hospital stay ± SD, 
  days
No. postoperative
  complication (%)
  (Clavien grade 3 or
  greater)
No. readmission (%)
Mean duration of 
  readmission 
  stay ± SD, days
27
82.5±2.1
23 (85.2)
  4 (14.8)
14 (51.9)
13 (48.1)
25 (92.6)
2 (7.4)
11 (40.7)
16 (59.3)
  3 (11.1)
24 (88.9)
21±20.2
  6 (22.2)
12 (44.4)
8.7±15.0
11
80.8±0.9
10 (90.9)
1 (9.1)
  8 (72.7)
  3 (27.3)
10 (90.9)
1 (9.1)
  5 (45.5)
  6 (54.5)
  2 (18.2)
  9 (81.8)
37±22.2
  5 (45.5)
  4 (36.4)
9.0±20.2
16
83.6±1.9
13 (81.3)
  3 (18.7)
  6 (37.5)
10 (62.5)
15 (93.8)
1 (6.2)
  6 (37.5)
10 (62.5)
1 (6.3)
15 (93.7)
10±7.6
1 (6.3)
  8 (50.0)
8.6±10.9
＜0.001
0.455
0.079
0.920
0.710
0.357
＜0.001
0.027
0.696
0.610
RC: radical cystectomy, Non-RC: non-radical cystectomy, CCI: 
Charlson comorbidity index, ASA: American Society of Anesthesi-
ologists, SD: standard deviation
TABLE 2. Clinicopathologic characteristics of the study cohort 
according to the Charlson-Comorbidity Index
Low CCI
(CCI=0)
High CCI
(CCI≥1)
p-value
No. patients 
Mean age±SD, years
No. gender (%)
    Male
    Female
No. ASA score (%)
    Low (1-2)
    High (3-4)
No. treatment modality (%)
    RC
    Non-RC
No. clinical tumor stage (%)
    Organ confined
    Extravesical
No. tumor grade (%)
    Grade 2
    Grade 3
Mean durationof hospital 
  stay ± SD, days
No. postoperative
  complication (%)
  (Clavien grade 3 or greater)
No. readmission (%)
Mean duration of readmission
  stay ± SD, days
14
82.4±2.4
12 (85.7)
  2 (14.3)
13 (92.9)
1 (7.1)
  8 (57.1) 
  6 (42.9)
  7 (50.0)
  7 (50.0)
  2 (14.3)
12 (85.7)
27.8±25.3
  6 (42.9)
  4 (28.6)
8.1±8.3
13
82.5±1.9
11 (84.6)
  2 (15.4)
12 (92.3)
1 (7.7)
  3 (27.3)
10 (72.7)
  4 (30.8)
  9 (69.2)
1 (7.7)
12 (92.3)
14.4±9.7
  4 (30.8)
  8 (61.5)
9.4±11.2
0.550
0.673
0.366
0.079
0.144
0.529
0.185
0.695
0.128
0.239
CCI: Charlson comorbidity index, ASA: American Society of 
Anesthesiologists, SD: standard deviation, RC: radical cys-
tectomy, Non-RC: non-radical cystectomy.
grade of 3 or higher (p=0.027). There was no significant dif-
ference in these two groups in the number of patients who 
required readmission after treatment (p=0.696) or the du-
ration of readmission hospital stay (p=0.610). Stratifica-
tion of patients by CCI [low (CCI = 0) vs. high (CCI≥1)] in-
dicated no significant differences between these two 
groups (Table 2). More patients in the low CCI group under-
went RC, although this difference was not significant 
(p=0.079).
　During the follow-up period (mean duration, 27 months), 
22 patients (81.5%) died, including 4 patients (14.8%) who 
died from bladder cancer at a mean time of 20 months after 
initiation of treatment. Nine patients (81.8%) in the RC 
group died and 13 patients (81.3%) in the non-RC group 
died (p=0.684). Two patients died from disease progression 
in each group, 2 patients underwent RC, 1 patient under-
went partial cystectomy, and 1 patient underwent TURB 
only. All patients who died from bladder cancer had clin-
ically or pathologically advanced cancer (Table 3).
　There were no significant differences in overall survival 
or cancer-specific survival between the RC and non-RC 
groups (overall survival, p=0.487; cancer-specific survival, Korean J Urol 2011;52:446-451
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FIG. 1. (A) Overall survival (left) and cancer-specific survival (right) according to treatment modality, (B) Overall survival (left) and
cancer-specific survival (right) according to tumor stage, (C) Overall survival (left) and cancer-specific survival (right) according to
Charlson Comorbidity Index (CCI).
p=0.994). Five-year overall survival was 27.3% in the RC 
group and 19.4% in the non-RC group (Fig. 1). Patients with 
organ-confined disease had better overall survival and can-
cer-specific survival than did patients with extravesical 
disease (overall survival, p=0.001, cancer-specific surviv-
al, p=0.014). Comparison of patients with low CCI and high 
CCI indicated no significant difference in cancer-specific 
survival (p=0.146), although overall survival was better in 
the low CCI group (p=0.013). Univariate analysis indicated 
that sex, clinical tumor stage, and CCI were associated 
with overall survival (Table 4). Multivariate Cox re-
gression analysis indicated that clinically organ-confined 
disease and low CCI were associated with better overall 
survival. Treatment modality was not associated with 
overall survival.Korean J Urol 2011;52:446-451
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TABLE 4. Univariate and multivariate Cox regression analysis of overall survival in octogenarians with muscle-invasive bladder 
cancer
Univariate Multivariate 
HR (95% CI) p-value  HR (95% CI) p-value 
Treatment modality (Non-RC vs. RC)
Age (continuous variable)
Gender (female vs. male)
CCI (high vs. low)
ASA (high vs. low)
Clinical tumor stage
  (extravesical vs organ confined)
Tumor grade (Grade 3 vs. Grade 2)
0.73 (0.30-1.78)
1.08 (0.89-1.30)
  5.02 (1.31-19.25)
3.31 (1.23-8.94)
3.54 (0.77-16.2)
  6.45 (2.24-18.56)
1.77 (0.40-7.86)
0.490
0.447
0.019
0.018
0.104
0.001
0.451
-
-
1.27 (0.30-5.35)
  3.36 (1.08-10.44)
-
  6.72 (2.05-22.09)
-
-
-
0.745
0.036
-
0.002
-
RC: radical cystectomy, Non-RC: non-radical cystectomy, CCI: Charlson comorbidity index, ASA: American Society of Anesthesiologists, 
HR: hazard ratio, CI: confidence interval.
DISCUSSION
Age is often a major consideration when weighing treat-
ment options for elderly patients with MIBC. However, 
some research indicates that RC can be safely performed 
in elderly patients, especially in octogenarians, with ac-
ceptable mortality and morbidity [15,16]. In the current 
study, 1 patient (9.1%) in the RC group died within the first 
90 days after radical cystectomy, similar to the mortality 
previously reported (0 to 18%) [17]. The incidence of major 
complications after radical cystectomy in the present study 
(45.5%) was also within the range reported in previous 
studies of treatment of bladder cancer patients of all ages 
(7.7% to 67.0%) [6-9,18-20].
　In octogenarians, however, overall survival is more im-
portant than definite cancer control, because of the short 
life expectancy of these patients (7.8 years for males and 
9.3 years for females of age 80; 5.8 years for males and 6.8 
years for females of age 85) [21]. There has been no con-
sensus about the survival benefit provided by RC in octoge-
narians [22,23]. In the current study, we found no sig-
nificant difference in cancer-specific survival or overall 
survival between the RC and non-RC groups, despite the 
younger mean age of the RC group. Although tumor re-
currence was more common in the non-RC group (p=0.051), 
most patients died from other causes before disease 
progression. Thus, we suggest that the general condition 
of patients be carefully evaluated before determining 
treatment modality for octogenarians with MIBC.
　We also evaluated CCI and ASA scores to assess the con-
ditions of the patients. When patients were stratified by 
CCI, those with low scores had better overall survival. This 
result agrees with a previous study that reported that pa-
tients with high age-adjusted CCI scores had poorer prog-
noses [24]. However, we found that ASA score did not pro-
vide clinically valuable information, because most patients 
had ASA scores of 2.
　As expected, we found that tumor stage was an im-
portant predictor of survival. Although treatment modal-
ity was not associated with overall survival, CCI was asso-
ciated with overall survival. Thus, CCI and tumor stage 
provide clinicians with valuable information in consider-
ing treatment modality. Octogenarians without comorbid-
ities and with clinically organ-confined disease seemed to 
have better overall survival, whereas octogenarians with 
one or more comorbidities or with extravesical disease 
seemed to have poorer survival despite radical surgery. 
Thus, treatment modality should be carefully considered 
after assessment of tumor stage and CCI. 
　Patient quality of life after treatment is another im-
portant issue. In general, RC effectively reduces symptoms 
and relapses, and recent studies have reported improved 
quality of life after RC in elderly patients [8]. We evaluated 
the number of readmissions and the duration of the read-
mission stay to assess quality of life and found no sig-
nificant difference between the RC and non-RC groups. 
Thus, the short hospital stays after treatment in the 
non-RC group indicates that alternative management pro-
vides comparable quality of life, as previously reported 
[25]. However, symptom improvements were not assessed 
in this study, although urinary symptoms, such as gross 
hematuria and dysuria are important factors for evaluat-
ing quality of life. Symptom improvements were reported 
as one of the greatest advantages of RC. In this regard, 
quality of life after RC was considered to be undervalued.
The current study was limited by its retrospective design 
and small number of patients. Another limitation was that 
three different treatment modalities were classified to-
gether as the non-RC group. Because of the small number 
of patients given each treatment modality, we could not 
evaluate the efficacy of each treatment separately. Finally, 
we used clinical staging instead of pathologic staging.
CONCLUSIONS
Although RC can be safely provided in selected octoge-
narian patients who have MIBC, RC in octogenarians with 
MIBC does not improve overall survival compared with 
other treatment modalities. Low CCI score and clinically 
organ-confined disease were independently associated Korean J Urol 2011;52:446-451
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with better overall survival and should be considered be-
fore selecting the treatment modality for elderly patients 
with MIBC. 
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